Stopping Cancer Before It Starts

Antiva is developing novel topical therapies to treat pre-cancerous cervical lesions as well as the HPV infections that cause these lesions. Currently, there is no treatment for HPV infection; women must wait and see whether their infection clears by itself or progresses to more advanced disease. We are developing a first-in-class therapy that would give women the ability to treat themselves in the privacy of their own homes when their infection is first diagnosed. Our therapy also provides a non-surgical option for women whose disease is more advanced.

Our passionate, experienced team is dedicated to improving health outcomes and access to care worldwide by developing a simple and convenient non-surgical approach to treat HPV and precancerous lesions, supporting the World Health Organization’s global Cervical Cancer Elimination Initiative.

Antiva in the

May 5, 2023

ANNOUNCEMENT: ASCCP Presents Dr. Tom Cox with Lifetime Achievement Award Read more

April 27, 2023

Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO Read more